Special Issue "Aptamer-Based Therapeutics"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (30 June 2013)
Dr. Sotiris Missailidis
Department of Chemistry and Analytical Sciences, The Open University, Walton Hall, Milton Keynes, UK
Interests: pharmacogenomics; molecular recognition; biomarkers; DNA biomimetics; aptamers as DNA targeting; therapeutic and imaging agents; inflammation and cancer; organometallic drug; aptamers as therapeutic and diagnostic agents or as recognition elements in biosensor development
We invite authors to submit papers to Pharmaceuticals in the exciting field of Aptamer research. This special issue is to include original papers and review articles on basic or clinical research on aptamers, including aptamer selection methodologies, aptamer conjugates, aptamer nanoparticles, spiegelmers, peptide aptamers, locked aptamers and different aptamer applications, including applications in diagnostics, imaging, therapy, sensors or other technology development, aptamer pharmacology, biomarker discovery or clinical applications.
Dr. Sotiris Missailidis
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- aptamer Selection
- aptamer conjugates
- aptamer nanoparticles
- peptide aptamers
- DNA aptamers
- RNA aptamer
- locked aptamers
- aptamer conjugates
- aptamer nanoparticles
- aptamer diagnostics
- aptamer therapeutics
- aptamer radiopharmaceuticals
- aptamers in oncology
- aptamer metabolism
- aptamer pharmacology
- clinical trials
Pharmaceuticals 2013, 6(12), 1507-1542; doi:10.3390/ph6121507
Received: 17 October 2013; in revised form: 12 November 2013 / Accepted: 15 November 2013 / Published: 25 November 2013| PDF Full-text (567 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2013, 6(9), 1082-1093; doi:10.3390/ph6091082
Received: 1 July 2013; in revised form: 11 August 2013 / Accepted: 26 August 2013 / Published: 29 August 2013| PDF Full-text (783 KB) | HTML Full-text | XML Full-text
Article: The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells
Pharmaceuticals 2013, 6(8), 960-987; doi:10.3390/ph6080960
Received: 8 July 2013; in revised form: 14 August 2013 / Accepted: 16 August 2013 / Published: 20 August 2013| PDF Full-text (1590 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2013, 6(3), 340-357; doi:10.3390/ph6030340
Received: 16 February 2013; in revised form: 9 March 2013 / Accepted: 11 March 2013 / Published: 19 March 2013| Cited by 2 | PDF Full-text (458 KB) | HTML Full-text | XML Full-text
Review: Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?
Pharmaceuticals 2012, 5(5), 493-513; doi:10.3390/ph5050493
Received: 5 March 2012; in revised form: 19 April 2012 / Accepted: 10 May 2012 / Published: 18 May 2012| Cited by 1 | PDF Full-text (959 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2012, 5(1), 49-60; doi:10.3390/ph5010049
Received: 28 November 2011; in revised form: 15 December 2011 / Accepted: 22 December 2011 / Published: 28 December 2011| Cited by 1 | PDF Full-text (456 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2011, 4(11), 1434-1449; doi:10.3390/ph4111434
Received: 22 September 2011; in revised form: 13 October 2011 / Accepted: 24 October 2011 / Published: 27 October 2011| Cited by 2 | PDF Full-text (254 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2011, 4(9), 1216-1235; doi:10.3390/ph4091216
Received: 1 August 2011; in revised form: 2 September 2011 / Accepted: 9 September 2011 / Published: 20 September 2011| Cited by 8 | PDF Full-text (805 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2011, 4(8), 1137-1157; doi:10.3390/ph4081137
Received: 6 July 2011; in revised form: 4 August 2011 / Accepted: 11 August 2011 / Published: 15 August 2011| Cited by 16 | PDF Full-text (1106 KB) | HTML Full-text | XML Full-text
Article: RNA Detection in Live Bacterial Cells Using Fluorescent Protein Complementation Triggered by Interaction of Two RNA Aptamers with Two RNA-Binding Peptides
Pharmaceuticals 2011, 4(3), 494-508; doi:10.3390/ph4030494
Received: 28 December 2010; in revised form: 17 January 2011 / Accepted: 11 February 2011 / Published: 10 March 2011| Cited by 5 | PDF Full-text (550 KB) | HTML Full-text | XML Full-text
Pharmaceuticals 2011, 4(2), 419-428; doi:10.3390/ph4020419
Received: 14 January 2011; in revised form: 8 February 2011 / Accepted: 16 February 2011 / Published: 18 February 2011| Cited by 5 | PDF Full-text (358 KB) | HTML Full-text | XML Full-text
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Type of Paper: Review
Title: Coupling Aptamers to short Interfering RNAs as Therapeutics
Authors: Vittorio de Franciscis and Laura Cerchia
Affiliation: Istituto per l’Endocrinologia e l’Oncologia Sperimentale del CNR ‘‘G. Salvatore’’, Via S. Pansini 5, 80131 Naples, Italy;
E-Mail: firstname.lastname@example.org (V.d.F.)
Abstract: RNA-based approaches are among the most promising strategies aimed at developing safer and more effective therapeutics. RNA therapeutics include small non-coding miRNAs, small interfering RNA, RNA aptamers and more recently small activating RNAs. However, major barriers exist to the use of RNAs as therapeutics as for example: resistance to nucleases present in biological fluids, chemical stability, need of specific cell targeted delivery and easy entry in the cell. Such issues have been addressed by several recent reports that show the possibility to introduce chemical modifications in small RNAs to stabilize the molecular conformation and increase of several folds integrity still preserving their functional activity. Further, several aptamers have been developed as excellent candidates for the specific recognition of cell surface targets. In the recent few years by taking advantage of recent advances in small RNA field molecular bioconjugates have been designed that permit specific targeting and may act as cargoes for cell internalization of small RNAs acting on gene expression that will be discussed in this Review.
Last update: 23 November 2012